Synthetix Bio

Premium Testing in Calgary, Alberta
Verification result

NAD+ 500mg

Public analytical testing record from Synthetix Bio.

← New search
✓ Certificate verifiedAuthentic report record
Product

NAD+ 500mg

Batch ND276543-1COA SB-20261016-00093Peptora Peptide Labs
Sample received2026-10-05
Analysis conducted2026-10-13
Sample typeLyophilized Powder Vial
Report issued2026-10-14
Purity99.7 %
Quantity (actual)500.6 mgLabeled: 500mg
Analytical results

Passed all tests

TestResult
Purity (%)99.7 %
Net content (mg)500.6 mg
IdentityNAD+
Endotoxin (EU/mL)0.03 EU/mL
SterilityNo growth
Heavy metals summary (ppm)< 0.1 ppm
Arsenic — As (ppm)0.067 ppm
Cadmium — Cd (ppm).0011 ppm
Lead — Pb (ppm)0.08 ppm
Mercury — Hg (ppm)0.016 ppm
Fentanyl presence analysisNot Present
Batch conformity
VialPurityNet content
V199.78500.2
V299.77500.4
V399.8500.6
Three-vial comparison

Purity (%)

025507510099.78 %V199.77 %V299.8 %V3

Net content (mg)

0143.92287.85431.77575.69500.2 mgV1500.4 mgV2500.6 mgV3

Charted from the entered per-vial results. Purity and net content use separate scales. This is a results comparison, not a chromatogram.

Molecular formula

C21H27N7014P2

CAS number

2387871217

Cap colour / description

White

Laboratory sample ID

SB-20170502

Chromatogram method

RP-HPLC (USP )

Column

C18, 4.6 x 150 mm, 3.5 μm

Detection

UV 214 nm

Retention time

7.88 min

Methods / reporting limits / test conditions

All chemical analyses were performed by HPLC with UV detection coupled with mass spectrometry.

Jonathan KowzkiLaboratory DirectorSynthetix Bio · Calgary, Alberta

Report version 3 · Last saved 2026-10-16 17:05:29. Verification confirms the issued record, separately from analytical outcomes. Findings apply to the submitted sample and stated test conditions. This report does not establish suitability for human use or regulatory approval.

Scroll to Top